International journal of molecular sciences

RNA-Based Treatments for Multiple Myeloma: From Targeting Molecules to Delivery and Patient Use

Updated

Abstract

Innovative may offer new strategies for treating .

  • Multiple myeloma is characterized by clonal plasma cell proliferation, leading to significant morbidity and mortality.
  • Current treatments, including chemotherapy and CAR-T therapies, have not achieved a cure due to challenges like tumor heterogeneity and immune evasion.
  • RNA-based approaches, such as mRNA vaccines, small interfering RNAs, antisense oligonucleotides, and microRNA mimics/inhibitors, are being explored for their therapeutic potential.
  • RNA-engineered cell therapies, including transient CAR-T platforms and lipid nanoparticle systems, are being investigated for targeting the bone marrow niche.
  • These RNA technologies may help achieve durable remissions and reduce treatment costs in refractory multiple myeloma.

Simplified

Full Text

What this is

  • () is a complex blood cancer with high mortality rates and limited treatment options.
  • This review evaluates innovative RNA-based therapies targeting , including mRNA vaccines, siRNAs, and engineered cell therapies.
  • It discusses the mechanisms of RNA therapeutics and their potential to overcome resistance and improve patient outcomes.

Essence

  • RNA-based therapies represent a promising frontier in treating , aiming to enhance efficacy and safety while addressing treatment resistance. These modalities include mRNA vaccines, siRNAs, and engineered cell therapies designed to target the unique challenges posed by .

Key takeaways

  • could transform treatment by enabling precise targeting of oncogenic pathways and immune modulation. These approaches include mRNA vaccines and RNA-engineered cell therapies that aim to enhance immune response and overcome resistance mechanisms.
  • Current therapies are limited by high costs and significant toxicities. RNA modalities, which allow for transient expression and programmable delivery, have the potential to reduce these challenges and improve patient outcomes.

Caveats

  • Despite the promise of RNA-based therapies, many remain in preclinical stages, and their clinical efficacy and safety are yet to be fully established.
  • Challenges such as efficient delivery to the bone marrow microenvironment and the need for optimized dosing regimens may hinder the rapid translation of these therapies into clinical practice.

Definitions

  • multiple myeloma (MM): A hematologic malignancy characterized by the uncontrolled proliferation of plasma cells in the bone marrow.
  • RNA-based therapeutics: Therapies that utilize RNA molecules, such as mRNA, siRNA, or ASOs, to modulate gene expression or target specific pathways.

Simplified

Funding

Competing interests

The authors declare no conflicts of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free